JP2023530500A - てんかんの治療におけるカンナビジオールの使用 - Google Patents

てんかんの治療におけるカンナビジオールの使用 Download PDF

Info

Publication number
JP2023530500A
JP2023530500A JP2022578719A JP2022578719A JP2023530500A JP 2023530500 A JP2023530500 A JP 2023530500A JP 2022578719 A JP2022578719 A JP 2022578719A JP 2022578719 A JP2022578719 A JP 2022578719A JP 2023530500 A JP2023530500 A JP 2023530500A
Authority
JP
Japan
Prior art keywords
cbd
caffeine
cannabidiol
dose
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022578719A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530500A5 (https=
Inventor
ジエ・リー
ケヴィン・ジェームズ・クレイグ
ダニエル・アダム・チェケッツ
デイヴィッド・ジョン・クリッチリー
Original Assignee
ジーダブリュー・リサーチ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジーダブリュー・リサーチ・リミテッド filed Critical ジーダブリュー・リサーチ・リミテッド
Publication of JP2023530500A publication Critical patent/JP2023530500A/ja
Publication of JP2023530500A5 publication Critical patent/JP2023530500A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022578719A 2020-06-18 2021-06-16 てんかんの治療におけるカンナビジオールの使用 Pending JP2023530500A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2009321.7A GB202009321D0 (en) 2020-06-18 2020-06-18 Use of cannabinoids in the treatment of epilepsy
GB2009321.7 2020-06-18
PCT/GB2021/051520 WO2021255446A1 (en) 2020-06-18 2021-06-16 Use of cannabidiol in the treatment of epilepsy

Publications (2)

Publication Number Publication Date
JP2023530500A true JP2023530500A (ja) 2023-07-18
JP2023530500A5 JP2023530500A5 (https=) 2024-06-25

Family

ID=71838306

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022578719A Pending JP2023530500A (ja) 2020-06-18 2021-06-16 てんかんの治療におけるカンナビジオールの使用

Country Status (11)

Country Link
US (1) US20230225986A1 (https=)
EP (1) EP4167980B1 (https=)
JP (1) JP2023530500A (https=)
KR (1) KR20230026337A (https=)
CN (1) CN115916168A (https=)
AU (1) AU2021291128A1 (https=)
CA (1) CA3181694A1 (https=)
GB (2) GB202009321D0 (https=)
MX (1) MX2022016038A (https=)
TW (1) TW202214217A (https=)
WO (1) WO2021255446A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
AU2024300440A1 (en) * 2023-07-25 2026-03-12 Algorae Pharmaceuticals Ltd Compositions and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017531667A (ja) * 2014-10-14 2017-10-26 ジーダブリュー・ファーマ・リミテッドＧｗ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ 癲癇の治療におけるカンナビノイドの使用
JP2018521042A (ja) * 2015-06-17 2018-08-02 ジーダブリュー リサーチ リミテッド てんかんの治療におけるカンナビノイドの使用
WO2019097238A1 (en) * 2017-11-15 2019-05-23 GW Research Limited Use of cannabinoids in the treatment of seizures associated with lennox-gastaut syndrome
CN109985042A (zh) * 2017-12-29 2019-07-09 汉义生物科技（北京）有限公司 一种含有大麻二酚或大麻提取物和咖啡因的组合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015308546A1 (en) * 2014-08-25 2017-04-13 Clk Consult V/ Carsten Leonhard Knudsen Device with compositions for delivery to the lungs, the oral mucosa and the brain
US20180360771A1 (en) * 2017-06-14 2018-12-20 Yury Leon Shmerlis Cannabidiol chewing gum
US20200172841A1 (en) * 2018-12-04 2020-06-04 Donald F. Wilkes Alcohol-free wine beverage

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017531667A (ja) * 2014-10-14 2017-10-26 ジーダブリュー・ファーマ・リミテッドＧｗ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ 癲癇の治療におけるカンナビノイドの使用
JP2018521042A (ja) * 2015-06-17 2018-08-02 ジーダブリュー リサーチ リミテッド てんかんの治療におけるカンナビノイドの使用
WO2019097238A1 (en) * 2017-11-15 2019-05-23 GW Research Limited Use of cannabinoids in the treatment of seizures associated with lennox-gastaut syndrome
CN109985042A (zh) * 2017-12-29 2019-07-09 汉义生物科技（北京）有限公司 一种含有大麻二酚或大麻提取物和咖啡因的组合物及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EXPERT OPIN DRUG METAB TOXICOL, vol. 10(7):981-989, JPN6025027109, 2014, ISSN: 0005636844 *
PEDIATRIC NEUROLOGY, vol. 96:24-29, JPN6025027108, 2019, ISSN: 0005636843 *
PHARMACOL BIOCHEM BEHAV, vol. 54(4):639-644, JPN6025027110, 1996, ISSN: 0005636845 *

Also Published As

Publication number Publication date
EP4167980A1 (en) 2023-04-26
AU2021291128A1 (en) 2022-12-01
CA3181694A1 (en) 2021-12-23
KR20230026337A (ko) 2023-02-24
CN115916168A (zh) 2023-04-04
GB202009321D0 (en) 2020-08-05
TW202214217A (zh) 2022-04-16
WO2021255446A1 (en) 2021-12-23
MX2022016038A (es) 2023-02-02
GB202108690D0 (en) 2021-08-04
US20230225986A1 (en) 2023-07-20
GB2598187A (en) 2022-02-23
EP4167980B1 (en) 2025-07-16

Similar Documents

Publication Publication Date Title
GB2593590A (en) Methods of treating tuberous sclerosis complex with cannabibiol and everolimus
JP5620647B2 (ja) 眠気覚まし用組成物
US10953056B2 (en) Natural product compositions for treating or managing symptoms of ADD, ADHD, anxiety, and depression
US11707465B2 (en) Theacrine-based supplement and method of use thereof in a synergistic combination with caffeine
US11925645B2 (en) Enhanced caffeinated beverage composition
US20180344709A1 (en) Use of gaboxadol in the treatment of tinnitus
US20040171624A1 (en) Pharmaceutical composition for treating mood disorders
JP2023530500A (ja) てんかんの治療におけるカンナビジオールの使用
US20080081066A1 (en) Tea-Derived Compositions and Methods of Using Same for Cardiovascular Health
CN115279197A (zh) 增强型含咖啡因饮料组合物
UA129270C2 (uk) Композиція тразодону педіатричного призначення
US11173143B2 (en) Composition for decreasing serum uric acid level
US11439603B2 (en) Compositions for ameliorating, preventing or treating somnipathy including phloroglucinol as active ingredient and compositions for suppressing intolerance to or alleviating side effects of agonist at benzodiazepine binding site of GABA-A receptor including phloroglucinol as active ingredient
KR101864384B1 (ko) 콜린 알포세레이트를 유효성분으로 하는 쥐남의 치료, 개선 또는 예방용 조성물 및 방법
AU2018101586A4 (en) Uses of polydatin
AU2018270381B2 (en) Theacrine-based supplement and method of use thereof in a synergistic combination with caffeine
KR101457442B1 (ko) 감마오리자놀을 유효성분으로 하는 히스타민 수용체 길항제 조성물
JP6112767B2 (ja) 血液中の尿酸値を低下させるための組成物
CURRENT SAFETY ISSUES OF CURRENT INTEREST

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240614

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240614

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260422